Navigation Links
Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Date:8/19/2007

for the treatment of Fabry disease and Plicera(TM) for the treatment of Gaucher disease. The Company is also conducting Phase I clinical trials of AT2220 for the treatment of Pompe disease.

Forward-Looking Statements

Amicus cautions you that statements included in this press release that are not a description of historical facts are "forward-looking statements" within the meaning of Section 21E of the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should," and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the potential progress and results of clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the business of Amicus, including, without limitation: the respective Phase II clinical trials for Amigal(TM) and Plicera(TM), and the Phase I clinical trial for AT2220 may not proceed in the timeframes or in the manner Amicus expects or at all. Further, the results of earlier clinical trials may not be predictive of future results; Amicus and its licensors may not be able to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of its product candidates; and other risks detailed in the public filings of Amicus with
'/>"/>

SOURCE Amicus Therapeutics

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Amicus Therapeutics Presents Positive Results From Phase 1 Clinical Studies of Plicera for Gaucher Disease
2. Amicus Therapeutics Presents Preclinical Data from Studies of Plicera for Gaucher Disease
3. Amicus Therapeutics Presents Data From Preclinical and Phase 1 Studies of Amigal for Fabry Disease
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
7. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
8. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
9. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
10. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
11. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the ... Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) ... in order to treat dental impairments, for tooth restoration ...
(Date:1/15/2014)... 15, 2014  Novation, the leading health care supply chain ... value-added reseller (VAR) national contracts that expand its portfolio ... at lower costs. These include manufacturer product and service ... assistance and ongoing IT consulting support. ...
(Date:1/15/2014)... , January 15, 2014 Shire plc (LSE: ... the Office of Fair Trading (OFT) approval condition to the announced ... (NASDAQ: VPHM).   As a result of the waiver, ... expects to complete the tender offer on January 24, 2014 following ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
(Date:4/17/2014)... study published today in PLOS Pathogens , children ... is common can mount an immune response to infection ... repeated bouts of high fever and illness and partially ... The findings may help researchers develop future interventions that ... parasite. , Each year, approximately 200 million cases of ...
(Date:4/17/2014)... in the April issue of Immunity , Kevin ... Medical Research, says it,s time to take a fresh ... sepsis, which kills millions worldwide every year, including ... released into the bloodstream to fight an injury or ... for maintaining good health without inflammation, wounds and ...
(Date:4/17/2014)... 17, 2014) Doctors who treat patients with ... (LAM) can face an agonizing treatment decision. , ... disease and help relieve shortness of breath. But ... sirolimus can cause potentially fatal complications following transplantation. ... Daniel Dilling, medical director of Loyola University Medical ...
(Date:4/17/2014)... April 17, 2014 By discovering a new mechanism ... a stroke, researchers at UC Irvine and the Salk ... may limit or prevent stroke-induced brain damage. , A ... cause of death and primary reason for disability in ... a stroke and lets blood-borne material into the brain, ...
(Date:4/17/2014)... potential to ward off depression among retirees, particularly among ... in The Journals of Gerontology, Series B: ... article " Internet Use and Depression Among Retired Older ... the authors report that Internet use reduced the probability ... study sample. , Late-life depression affects between 5 ...
Breaking Medicine News(10 mins):Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Internet use may cut retirees' depression 2
... not only for tomato lovers around the country but also ... for millions of people. , In research published June 4 ... they,ve identified a molecular trick that may explain part of ... Medical Center has identified a protein that allows the bacteria ...
... Detection of Brain Injury Is Key, WASHINGTON, ... Rehabilitation Hospital (NRH) will fly to Germany on ... Medical Command (ERMC), in,assessing their current rehabilitation practices. ... and delivery of care given to,injured soldiers and ...
... Birner Dental Management,Services, Inc. (Nasdaq: BDMS ... regular quarterly dividend. The Company,s board of directors,has ... per share of common,stock. The dividend is payable ... 2008., Birner Dental Management Services, Inc. acquires, ...
... over next 60 days to try to resolve remaining ... company,PreMD Inc. (TSX: PMD; Amex: PME) today announced that ... and Drug Administration (FDA) in an,effort to resolve the ... non-invasive skin cholesterol test. Over the,next 60 days PreMD ...
... they fret about kids, knowledge of safety, privacy, emergency practices, ... (HealthDay News) -- Many parents leave their tweens home alone ... not confident these 11- to 13-year-olds have the knowledge or ... The University of Michigan C.S. Mott Children,s Hospital National Poll ...
... to Narconon,Trois-Rivieres, drug addiction is not a random ... in most instances by a problem, a particular,discomfort, ... individual,cannot handle or fix. The individual will find ... *(PHOTO Link: Send2Press.com/mediaboom/08-0613-Narconon_72dpi.jpg), (Photo Caption: Drug ...
Cached Medicine News:Health News:Salmonella: Trickier than we imagined 2Health News:Salmonella: Trickier than we imagined 3Health News:National Rehabilitation Hospital Team to Work with US Army to Improve Rehab Care for Wounded Soldiers 2Health News:National Rehabilitation Hospital Team to Work with US Army to Improve Rehab Care for Wounded Soldiers 3Health News:National Rehabilitation Hospital Team to Work with US Army to Improve Rehab Care for Wounded Soldiers 4Health News:National Rehabilitation Hospital Team to Work with US Army to Improve Rehab Care for Wounded Soldiers 5Health News:PreMD Reports Further Positive Meetings with the FDA 2Health News:Parents Worry About Tweens Left Alone 2Health News:Drug Addiction Explained by Drug Addiction Center 2
Anti Gliadin IgA Enzyme Immunosay for quantitative determination of Gliadin-IgG antibodies in serum....
... WorkCell System - A Single Platform ... hour, with true load-and-go productivity and ... Atlas and UF-100 for complete walkaway ... working together deliver utmost reliability. Ease ...
... high throughput primary or backup instrument, ... performance and reliability equal to or ... The advanced technology of the AUTION ... delivers reproducible and accurate results, limiting ...
... of the 3 major naturally occurring estrogens ... terms of estrogenic activity, estriol is much ... produced almost exclusively during pregnancy, and is ... human fetus. During pregnancy, the production of ...
Medicine Products: